Innate Pharma (Innate Pharma) FCF Margin % : -139.73% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Innate Pharma's Free Cash Flow for the six months ended in Dec. 2023 was $-25.23 Mil. Innate Pharma's Revenue for the six months ended in Dec. 2023 was $18.06 Mil. Therefore, Innate Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -139.73%.

As of today, Innate Pharma's current FCF Yield % is -19.23%.

The historical rank and industry rank for Innate Pharma's FCF Margin % or its related term are showing as below:

IPHA' s FCF Margin % Range Over the Past 10 Years
Min: -2257.66 Med: -74.8 Max: 1119.83
Current: -67.41

During the past 13 years, the highest FCF Margin % of Innate Pharma was 1119.83%. The lowest was -2257.66%. And the median was -74.80%.

IPHA's FCF Margin % is ranked better than
58.41% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs IPHA: -67.41

Innate Pharma FCF Margin % Historical Data

The historical data trend for Innate Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma FCF Margin % Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-44.42

-112.28

-493.69

-40.90

-67.26

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-744.85	1.93	-253.65	-33.31	-139.73

Competitive Comparison of Innate Pharma's FCF Margin %

For the Biotechnology subindustry, Innate Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Innate Pharma's FCF Margin % falls into.

Innate Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Innate Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-38.069	/	56.599
	=	-67.26 %

Innate Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-25.229	/	18.056
	=	-139.73 %

Innate Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Innate Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.